SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
Hair regrowth in transfems is more effective due to hormonal changes, specifically estrogen, which keeps hair in growth phase longer. Treatments mentioned include anti-androgens, sex hormones, and DHT blockers like finasteride.
A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.
The conversation is about someone who initially had positive results with Minoxidil for hair loss, lost those gains due to a hospital stay, and is now not seeing the same results upon resuming treatment. They plan to add microneedling and/or tretinoin to their regimen and are seeking success stories from others who did not respond to Minoxidil alone.
Vitamin E and K deficiencies due to exocrine pancreatic insufficiency may affect hair growth. A scalp biopsy is recommended to check for autoimmune-related hair loss.
Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
Stem cell and exosome injections for hair loss are discussed, with skepticism about their effectiveness and concerns about using non-genetically related stem cells. Dr. Deyarmin's treatments are mentioned, with some users questioning their legitimacy and others expressing curiosity.
The user is using topical Minoxidil, finasteride, tretinoin, redensyl, and dermastamping for hair loss treatment. There is debate about the effectiveness of these treatments, with suggestions to improve photo comparisons for better assessment.
Tazarotene may be more effective than tretinoin when combined with topical minoxidil for hair loss due to its selective binding to RAR-beta and gamma, though it can cause irritation. Tazarotene's potency can lead to indirect inflammatory reactions despite potentially causing less irritation than tretinoin.
The user experienced significant hair regrowth using Minoxidil, Finasteride, and Biotin, with no side effects or shedding after 8 months. They are concerned about potential future shedding but have been advised to continue their current routine.
The conversation discusses concerns about the effectiveness of RU58841 due to high temperatures during delivery. A user reassures that the heat will not affect its efficacy.
An 18-year-old experiencing hair loss and seborrheic dermatitis has tried finasteride, dutasteride, and various shampoos without success. They are considering anti-androgens like RU58841 and KX-826 for oil control and dandruff reduction.
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.
The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.
The conversation discusses scalp itching and tenderness after microneedling, despite using medicated shampoos and proper sanitation. The user plans to see a dermatologist and is concerned about possible infection or allergic reaction.
Hair regrowth treatments, including stem cell injections, are discussed, with skepticism about their effectiveness compared to Minoxidil and finasteride. Derma stamping is mentioned as effective when used with Minoxidil, finasteride, and dutasteride.
Minoxidil may not be effective due to low sulfotransferase activity, and the user considers adding tretinoin to the regimen. They are unsure about the timing and combination with microneedling.
A user is considering mixing Stemoxydine, RU-58841, Alfatradiol, and Tretinoin into a single topical solution for hair loss. They are concerned about potential interactions that could reduce the effectiveness of these ingredients.
The user experienced significant hair regrowth over 8 months using finasteride, minoxidil, and a custom topical mix including progesterone, cortisone, and alpha 5 estradiol. They reported no side effects and noticed improvement around the third month.
RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.
People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.
A user shared their experience on day 9 after a hair transplant, mentioning the use of vitamin E oil and conditioner to remove scabs. They received positive feedback on their progress and were advised to be patient for noticeable results in a few months.
The post humorously discusses an exaggerated hair loss treatment regimen including minoxidil, finasteride, microneedling, and "demon blood." Replies joke about the regimen and suggest alternative sources for "demon blood."
Hair follicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.
A recent discovery in hair cloning identified a previously unknown cell type essential for hair follicle growth, which could potentially make lab-grown hair viable if translated to humans. However, skepticism remains due to past delays and the challenges of replicating results in humans and making the process affordable.